Mild cognitive impairment !

Memory or thinking decline beyond normal ageing that still lets a person manage daily life. It may stay stable, improve or progress to dementia.

Updated 2026-11-01

Structures involved

Tap one to see what it is and open it in 3D.

Why it happens

What it is

A syndrome of objective decline in one or more cognitive domains (memory, attention, language, executive or visuospatial function), noticed by the person or others and confirmed by testing, with independence in daily activities essentially preserved. In current terminology it corresponds to mild neurocognitive disorder.

Who gets it

Prevalence rises with age, from about 7% at 60–64 years to about a quarter at 80–84 years, per the American Academy of Neurology guideline. Roughly 10–15% of people with MCI progress to dementia each year, more than people of the same age without it. With rapid population ageing and low schooling in older cohorts in Colombia and Latin America, MCI is a growing primary care problem, and education level must be considered when interpreting screening scores.

Causes

Early Alzheimer disease (most common cause of amnestic MCI)
Cerebrovascular disease (vascular cognitive impairment)
Lewy body disease and Parkinson disease
Early frontotemporal lobar degeneration
Potentially reversible contributors: depression, hypothyroidism, vitamin B12 deficiency, sleep apnea, medicines with anticholinergic or sedative effects, alcohol

Risk factors

Advanced age
APOE e4 carrier status
Hypertension, diabetes, dyslipidemia, obesity and smoking
Low education and low cognitive activity
Physical inactivity and social isolation
Hearing loss and depression
Prior stroke or head injury

Pathophysiology

MCI is a clinical stage on the path of several neurodegenerative and vascular diseases. In Alzheimer-type MCI, amyloid plaques and tau tangles first damage the entorhinal cortex and hippocampus, which encode new memories, so recent memory fails first. The brain compensates for a time (cognitive reserve), which keeps daily function intact until damage spreads to association cortices and dementia appears.

Classification

Amnestic MCI: memory is the main domain affected; highest risk of Alzheimer dementia
Non-amnestic MCI: language, executive or visuospatial domains affected; associated with vascular, Lewy body or frontotemporal causes
Single-domain or multiple-domain

Symptoms and signs

Forgetting recent conversations, appointments or events more than before
Repeating questions, losing objects more often
Difficulty finding words or following complex conversations
Slower planning or trouble with complex tasks (finances, medicines), with extra effort but still independent
Concern expressed by the person or family

Diagnosis

Clinical: History from the patient and an informant documenting change from previous level, plus functional assessment (instrumental activities of daily living largely preserved). Cognitive screening with tools such as MoCA or MMSE, adjusted for education, and neuropsychological testing when doubtful. Screen for depression, hearing and vision problems and review medicines.
Tests: Blood count, metabolic panel, thyroid function, vitamin B12 and, depending on risk, syphilis and HIV serology. Amyloid and tau biomarkers in cerebrospinal fluid or blood, or amyloid PET, can identify MCI due to Alzheimer disease in specialised settings.
Imaging: Brain MRI (or CT) excludes structural causes and shows vascular lesions or hippocampal atrophy.

Differential diagnosis

Normal cognitive ageing
Mild dementia (function already impaired)
Delirium
Depression with cognitive complaints
Medication effects, hypothyroidism or B12 deficiency

Goal of treatment

Identify and correct reversible causes, reduce vascular and lifestyle risk factors, preserve function and safety, and monitor for progression to dementia.

Treatment

Conservative: Regular aerobic and strength exercise, recommended by the American Academy of Neurology; cognitive training and social engagement may also help.
Conservative: Control of hypertension, diabetes and other vascular risk factors; correction of hearing loss; treatment of depression and sleep disorders; stopping anticholinergic and sedative drugs where possible.
Medical: No drug is proven to prevent progression of MCI; cholinesterase inhibitors are not routinely recommended. Anti-amyloid antibodies are used in selected patients with biomarker-confirmed early Alzheimer disease in specialised centres.
Follow-up: Re-evaluate cognition and function every 6 to 12 months; plan ahead early (advance directives, finances, driving) and support the family.

Complications

Progression to dementia
Medication errors and financial mistakes
Higher risk of delirium during illness or surgery
Driving and safety risks
Anxiety and depression after the diagnosis

Prognosis

Variable: a proportion of patients revert to normal cognition, especially when a reversible cause is treated, some stay stable, and others progress to dementia. Amnestic subtype and positive Alzheimer biomarkers predict progression.

Prevention

Physical activity, education and lifelong cognitive and social activity
Control of blood pressure, diabetes and cholesterol; not smoking
Treating hearing loss and depression
Limiting alcohol and avoiding unnecessary sedatives

Test yourself

Think of the answer, then tap the question to see it.

What distinguishes MCI from dementia?

In MCI independence in daily activities is preserved; in dementia it is lost.

Which MCI subtype carries the highest risk of Alzheimer dementia?

Amnestic MCI.

Which intervention does the AAN guideline recommend for patients with MCI?

Regular exercise.

Which three reversible causes should be checked in a patient with cognitive complaints?

Depression, hypothyroidism and vitamin B12 deficiency (also medicines and sleep apnea).

Approximately what proportion of people with MCI progress to dementia per year?

About 10–15%.

Add to my cards (5)

Educational information, not medical advice. For any symptom, see a health professional.

Sources: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology (Neurology, 2018); Mild Cognitive Impairment (MCI) (Alzheimer's Association, 2025).

← All conditions

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.

Hippocampus highlighted on the Durgical 3D model